Table 4. Multivariate analysis of DFS and OS for adenocacinoma patients harboring EGFR mutations.

Variable	DFS		OS
	HR (95% CI)	P-value	HR (95% CI)	P-value
EGFR-mutated (n = 218)
Clinical Stage (I–II vs. IIIA)	1.825 (1.205–2.762)	0.004	1.694 (1.025–2.802)	0.040
CEA (> 5 ng/ml vs. ≤ 5 ng/ml)
Cyfra21–1 (> 3.3 ng/ml vs.≤ 3.3 ng/ml)	1.543 (1.039–2.292)	0.032	2.527 (1.620–3.942)	< 0.001
Exon 19 deletion subgroup (n = 105)
Clinical Stage (I–II vs. IIIA)
CEA (> 5 ng/ml vs. ≤ 5 ng/ml)
Cyfra21–1 (> 3.3 ng/ml vs.≤ 3.3 ng/ml)			2.713 (1.229–4.428)	0.002
L858R substitution subgroup (n = 113)
Clinical Stage (I–II vs. IIIA)	2.234 (1.246–4.004)	0.007
CEA (> 5 ng/ml vs. ≤ 5 ng/ml)	2.259 (1.277–3.996)	0.005	2.515 (1.313–4.819)	0.005
Cyfra21–1 (> 3.3 ng/ml vs.≤ 3.3 ng/ml)			2.068 (1.087–3.933)	0.027
EGFR wild-type (n = 348)
Clinical Stage (I–II vs. IIIA)	1.527 (1.070–2.181)	0.02	1.593 (1.058–2.398)	0.026
CEA (> 5 ng/ml vs. ≤ 5 ng/ml)	2.150 (1.606–2.878)	< 0.001	1.711 (1.224–2.392)	0.002
Cyfra21–1 (> 3.3 ng/ml vs. ≤ 3.3 ng/ml)